Rockefeller Capital Management L.P. increased its holdings in Tandem Diabetes Care Inc (NASDAQ:TNDM) by 101.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,784 shares of the medical device company’s stock after purchasing an additional 1,904 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Tandem Diabetes Care were worth $226,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. FMR LLC grew its stake in Tandem Diabetes Care by 248.9% during the 1st quarter. FMR LLC now owns 705,789 shares of the medical device company’s stock worth $44,818,000 after purchasing an additional 503,482 shares in the last quarter. BlackRock Inc. raised its position in shares of Tandem Diabetes Care by 2.1% during the 2nd quarter. BlackRock Inc. now owns 4,054,911 shares of the medical device company’s stock worth $261,622,000 after acquiring an additional 83,336 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Tandem Diabetes Care by 10.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,210 shares of the medical device company’s stock worth $189,000 after acquiring an additional 316 shares in the last quarter. State of New Jersey Common Pension Fund D purchased a new stake in Tandem Diabetes Care during the third quarter worth approximately $2,542,000. Finally, Dupont Capital Management Corp lifted its stake in Tandem Diabetes Care by 3.7% during the third quarter. Dupont Capital Management Corp now owns 17,535 shares of the medical device company’s stock worth $1,034,000 after purchasing an additional 626 shares during the last quarter. Hedge funds and other institutional investors own 91.09% of the company’s stock.
A number of research analysts recently commented on TNDM shares. Piper Sandler increased their target price on shares of Tandem Diabetes Care from $70.00 to $90.00 and gave the company an “overweight” rating in a research report on Tuesday. Oppenheimer lifted their price target on shares of Tandem Diabetes Care from to in a research note on Tuesday. BidaskClub raised shares of Tandem Diabetes Care from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 20th. Craig Hallum upped their price objective on shares of Tandem Diabetes Care from $92.00 to $108.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Raymond James raised their price objective on Tandem Diabetes Care from $85.00 to $91.00 and gave the stock an “outperform” rating in a report on Tuesday. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Tandem Diabetes Care currently has a consensus rating of “Buy” and an average target price of $83.62.
TNDM traded down $0.77 during trading on Friday, reaching $74.28. The company’s stock had a trading volume of 81,545 shares, compared to its average volume of 1,731,421. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.05 and a current ratio of 2.78. The company’s fifty day moving average price is $75.76 and its 200-day moving average price is $65.90. Tandem Diabetes Care Inc has a 52-week low of $51.37 and a 52-week high of $91.65. The company has a market capitalization of $4.48 billion, a price-to-earnings ratio of -154.64 and a beta of 0.08.
Tandem Diabetes Care (NASDAQ:TNDM) last issued its earnings results on Monday, February 24th. The medical device company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. The business had revenue of $108.40 million during the quarter, compared to the consensus estimate of $109.22 million. Tandem Diabetes Care had a negative return on equity of 8.99% and a negative net margin of 6.83%. The company’s revenue for the quarter was up 42.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.02 EPS. Equities analysts predict that Tandem Diabetes Care Inc will post -0.01 earnings per share for the current year.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Featured Story: 52- Week Highs
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.